163 related articles for article (PubMed ID: 38101278)
1. Insights from the trends of omalizumab and mepolizumab utilization in patients with asthma: A population-based cohort study using the National Database in Japan.
Kan-O K; Noda T; Ogata H; Masaki K; Nishioka Y; Myojin T; Adachi T; Morita H; Imamura T; Tamari M; Kainuma K;
Respir Investig; 2024 Jan; 62(1):113-120. PubMed ID: 38101278
[TBL] [Abstract][Full Text] [Related]
2. Disease burden in patients with asthma before initiating biologics: A retrospective cohort database study.
Ortega H; Hahn B; Tran JN; Bell C; Shams SA; Llanos JP
Allergy Asthma Proc; 2019 May; 40(3):146-153. PubMed ID: 30925945
[No Abstract] [Full Text] [Related]
3. Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma: a long-term retrospective analysis.
Basagaña M; Martínez-Rivera C; Padró C; Garcia-Olivé I; Martínez-Colls M; Navarro J; Pardo L; Cruz P; Cardona Peitx G; Carabias L; Roger A; Abad J; Rosell A
Ann Med; 2024 Dec; 56(1):2317356. PubMed ID: 38364218
[TBL] [Abstract][Full Text] [Related]
4. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
Carpagnano GE; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Quarato CMI; Foschino Barbaro MP
Ther Adv Respir Dis; 2020; 14():1753466620929231. PubMed ID: 32482128
[TBL] [Abstract][Full Text] [Related]
5. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma.
Chapman KR; Albers FC; Chipps B; Muñoz X; Devouassoux G; Bergna M; Galkin D; Azmi J; Mouneimne D; Price RG; Liu MC
Allergy; 2019 Sep; 74(9):1716-1726. PubMed ID: 31049972
[TBL] [Abstract][Full Text] [Related]
6. Smaller Differences in the Comparative Effectiveness of Biologics in Reducing Asthma-Related Hospitalizations Compared With Overall Exacerbations.
Akenroye A; Marshall J; Simon AL; Hague C; Costa R; Jamal-Allial A; McMahill-Walraven CN; Haffenreffer K; Han A; Wu AC
J Allergy Clin Immunol Pract; 2024 Jun; 12(6):1568-1574.e2. PubMed ID: 38431251
[TBL] [Abstract][Full Text] [Related]
7. Real-world Omalizumab and Mepolizumab treated difficult asthma phenotypes and their clinical outcomes.
Fong WCG; Azim A; Knight D; Mistry H; Freeman A; Felongco M; Kyyaly A; Harvey M; Dennison P; Zhang H; Howarth P; Arshad SH; Kurukulaaratchy RJ
Clin Exp Allergy; 2021 Aug; 51(8):1019-1032. PubMed ID: 33866615
[TBL] [Abstract][Full Text] [Related]
8. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics.
Liu MC; Chipps B; Munoz X; Devouassoux G; Bergna M; Smith SG; Price RG; Galkin DV; Azmi J; Mouneimne D; Albers FC; Chapman KR
Respir Res; 2021 May; 22(1):144. PubMed ID: 33971856
[TBL] [Abstract][Full Text] [Related]
9. Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients.
Thomas D; McDonald VM; Stevens S; Harvey ES; Baraket M; Bardin P; Bowden JJ; Bowler S; Chien J; Chung LP; Gillman A; Hew M; Hodge S; James A; Jenkins C; Katelaris CH; Katsoulotos GP; Langton D; Lee J; Marks G; Peters M; Radhakrishna N; Reynolds PN; Rimmer J; Sivakumaran P; Upham JW; Wark P; Yang IA; Gibson PG
Allergy; 2024 Feb; 79(2):384-392. PubMed ID: 37632144
[TBL] [Abstract][Full Text] [Related]
10. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
[TBL] [Abstract][Full Text] [Related]
11. Comparative Impact of Asthma Biologics: A Nationwide US Claim-Based Analysis.
Al-Shaikhly T; Norris MR; Dennis EH; Liu G; Craig TJ
J Allergy Clin Immunol Pract; 2024 Jun; 12(6):1558-1567. PubMed ID: 38423294
[TBL] [Abstract][Full Text] [Related]
12. Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study.
Albers FC; Müllerová H; Gunsoy NB; Shin JY; Nelsen LM; Bradford ES; Cockle SM; Suruki RY
J Asthma; 2018 Feb; 55(2):152-160. PubMed ID: 28622052
[TBL] [Abstract][Full Text] [Related]
13. Biological treatments in childhood asthma.
Nieto-García A; Nieto-Cid M; Mazón-Ramos Á
Curr Opin Allergy Clin Immunol; 2024 Jun; 24(3):114-121. PubMed ID: 38567842
[TBL] [Abstract][Full Text] [Related]
14. Lung function trajectories in a cohort of patients with moderate-to-severe asthma on mepolizumab, omalizumab, or dupilumab.
Nopsopon T; Barrett NA; Phipatanakul W; Laidlaw TM; Weiss ST; Akenroye A
Allergy; 2024 May; 79(5):1195-1207. PubMed ID: 38164813
[TBL] [Abstract][Full Text] [Related]
15. [Patients in the IDEAL cohort: A snapshot of severe asthma in France].
Taillé C; Pison C; Nocent C; Devouassoux G; Prud'homme A; Gruber A; Gunsoy N; Albers F
Rev Mal Respir; 2019 Feb; 36(2):179-190. PubMed ID: 30429093
[TBL] [Abstract][Full Text] [Related]
16. Comparison of omalizumab and mepolizumab treatment efficacy in patients with atopic and eosinophilic "Overlap" severe asthma: Biological agent preference in atopic-eosinophilic severe asthma.
Tepetam FM; Akyildiz AB; Özden Ş; Örcen C; Yakut T; Atik Ö
Medicine (Baltimore); 2023 May; 102(18):e33660. PubMed ID: 37144999
[TBL] [Abstract][Full Text] [Related]
17. Clinical and economic burden of severe asthma among US patients treated with biologic therapies.
Reibman J; Tan L; Ambrose C; Chung Y; Desai P; Llanos JP; Moynihan M; Tkacz J
Ann Allergy Asthma Immunol; 2021 Sep; 127(3):318-325.e2. PubMed ID: 33775904
[TBL] [Abstract][Full Text] [Related]
18. Biologics and Bronchial Thermoplasty for severe refractory asthma treatment: From eligibility criteria to real practice. A cross-sectional study.
Menzella F; Galeone C; Ruggiero P; Bagnasco D; Catellani C; Facciolongo N
Pulm Pharmacol Ther; 2020 Feb; 60():101874. PubMed ID: 31857207
[TBL] [Abstract][Full Text] [Related]
19. [SWITCHING BIOLOGICS LED TO GOOD CONTROL IN SEVERE CHILDHOOD ASTHMA: A CASE REPORT].
Imai A; Takizawa T; Sato K; Inoue T; Nishida Y; Yagi H; Arakawa H
Arerugi; 2019; 68(7):869-873. PubMed ID: 31406083
[TBL] [Abstract][Full Text] [Related]
20. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment.
Magnan A; Bourdin A; Prazma CM; Albers FC; Price RG; Yancey SW; Ortega H
Allergy; 2016 Sep; 71(9):1335-44. PubMed ID: 27087007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
